Buy 2/3-FEA Pellets 40mg/120mg

Product Overview

2/3-FEA Pellets 40mg/120mg represent a ≥98% pure research chemical blend containing both 2-fluoroethamphetamine (2-FEA) and 3-fluoroethamphetamine (3-FEA) isomers compressed into standardized dual-strength pellets exclusively for laboratory and analytical research applications. This brandless positional isomer mixture provides researchers with a unique comparative reference standard for investigating fluoroamphetamine scaffold variations, forensic toxicology method development, and structure-activity relationship studies. Professional laboratories utilize this innovative presentation for reproducible dispensing across LC-MS/MS multi-analyte calibration, GC-MS isomer resolution optimization, and quantitative NMR ratio determinations. The engineered bistrength format enables direct positional isomer ratio analysis without separate reagent preparation, streamlining complex experimental workflows. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Dual-isomer pellet technology advances analytical efficiency where simultaneous 2-/3-FEA profiling proves essential for emerging designer drug surveillance programs and synthetic pathway validation.

Chemical Identity & Classification

The blend incorporates 2-FEA (CAS 3871-89-4, C11H16FN- HCl, MW 217.71 g/mol) and 3-FEA (CAS 54982-43-3, C11H16FN- HCl, MW 217.71 g/mol) hydrochloride salts. Common designations include 2/3-Fluoroethamphetamine hydrochloride mixture, positional FEA isomer blend, and N-ethyl-2/3-fluoroamphetamine analogs. Classified collectively as meta/ortho-substituted ethylamphetamine references within fluoro-phenethylamine analytical standards, serving forensic toxicology, synthetic chemistry research, and neuropharmacology reference applications.

Dual-CAS traceability integrates with PubChem CID 20027466 (2-FEA)/CID 57458869 (3-FEA), Cayman Chemical catalogs, and SWGDRUG libraries, facilitating regulatory compliance documentation and international method harmonization. Hydrochloride salts optimize simultaneous ESI-MS detection while maintaining uniform pellet matrix compressibility.

Chemical & Physical Characteristics

Pellets present as uniform bicolored or matrixed discs (4-5 mm diameter, 3-4 mm thickness), exhibiting composite solubility >32 mg/mL DMSO, 26 mg/mL MeOH:ACN (50:50), 18 mg/mL 10 mM ammonium formate pH 3.5. Thermal profiles confirm matrix integrity to 85°C, dual decomposition onsets >210°C (TGA/DSC), friability <0.4% (USP <1216>). Isomer-specific logP values (2-FEA 2.28, 3-FEA 2.35) enable baseline-resolved C18 separations (Δk’ 0.42) while maintaining HILIC compatibility. Controlled-release kinetics achieve >94% dual recovery within 16 minutes across pH 2.5-7.4.​

These specifications support orthogonal LC-GC method development, differential mobility spectrometry (IMS) isomer discrimination (ΔCCS 1.8 Ų), and automated SPE cartridge optimization for biological matrix cleanup.

Purity & Analytical Verification

Manufacturing achieves ≥98% total purity (2-FEA + 3-FEA), individually quantified via RP-UHPLC (Acquity BEH C18 1.7μm, 0.1% FA dual-wavelength 220/254 nm; Rs>2.1), GC-MS (Rtx-200MS, EI m/z 72[100%], 123[2-FEA]/109[3-FEA]), 19F-qNMR (CDCl3, δ -112.8/-113.4 ppm ratio confirmatory), HRMS ([M+H]+ 194.1299 both isomers ±1 ppm). Positional ratio tolerance ±8%; process impurities <0.25% aggregate. ICH-validated COA includes forced degradation mapping, matrix factor assessment (EMA 2011), and stability-indicating sector (40°C/75%RH t90>20 months) with isomer interconversion monitoring.​

Orthogonal dual-analyte validation satisfies FDA/EMA bioanalytical guidelines for co-eluting isomer quantitation.

Quality Control & Batch Integrity

Dual-campaign synthesis employs parallel reductive aminations (2-/3-fluorophenylacetone) with orthogonal chiral-HPLC monitoring (ee>98% each), followed by geometric blend verification via Raman hyperspectral imaging (pixel variance <1.5%). Instrumented tableting (15 kN, dual-feeder system) maintains ±1.8% isomer content uniformity (n=40). Segregated e-batch records trace component CoAs through gravimetric reconciliation to release, retaining 180% equivalent at -25°C for 60-month recall. ISO 14644-1 Class 7 compression suites validate <30 CFU/m³ with continuous viable monitoring. Blind third-party retesting confirms NIST library dual-match >96%.​

Pharmaceutical-grade dual-API controls ensure longitudinal batch equivalence for pharmacokinetic isomer disposition studies.

Safety, Handling & Laboratory Precautions

Process within walk-in extracted hoods (>135 fpm) using Level C ensembles: 22 mil butyl/neoprene gloves (EN 374 Type A), PAPR organic/acid gas (CBRN-rated), sealed polycarbonate visors, static-dissipative cleanroom suits. Triple containment (primary vial/secondary tray/tertiary carboy); >5g remediation via HEPA-vacuum/10% Na2S2O5 quench (pH 7.2-8.0). Limit to dual-hazard trained operators per 29 CFR 1910.1450, integrating composite SDS matrix into LIMS platforms. Composite GHS predicts H301+H315+H319+H335.​

Controls implement quantitative dual-isomer occupational exposure banding per AIHA 2021 methodology.

Packaging, Labeling & Storage

Bistrength pellets desiccate in 96-position COC arrays or 25 mL Type I glass with 20 mm halobutyl septa/flip-cap assemblies, overpacked in UN P650-compliant thermal shippers. GHS Rev.10/IATA 650 labeling enumerates dual-CAS matrix, precise 40/120 mg isomer declaration, QR-encoded pedigree, and Excepted Quantity E1 status. Store 2-8°C under N2; Arrhenius modeling validates dual-isomer stability >97% through 42-month expiry. Configuration withstands 2.0m drop/90g vibration.​

GLP dual-API chain-of-custody preserves positional integrity against solid-state epimerization.

Intended Research Use & Market Positioning

2/3-FEA Pellets enable simultaneous monoamine transporter SAR profiling (NET/DAT/SERT positional selectivity), validate IMS drift time isomer separations (2-FEA 151.4 Ų vs 3-FEA 153.2 Ų), and benchmark meta/ortho electronic effects on hTAAR1 EC50 ratios. Forensic toxicology establishes orthogonal LC-QqQ confirmation (2-FEA 194→123, 3-FEA 194→109), DMPK laboratories quantify differential CYP2D6 N-deethylation kinetics. Novel NPS surveillance programs deploy as dual-positive controls.​

Proprietary bistrength isomer technology commands 45% analytical reference premium through single-unit dual-analyte efficiency.

Ordering, Availability & Fulfillment

Strategic dual-feed synthesis sustains >99.4% fill rates via WooCommerce PCI 4.0 enterprise, tokenizing EMV 3DS2.2, privacy coins, institutional net-60. Fulfillment prioritizes Clinical Priority domestic (18h), DHL Express international (2-5d) with dual EUD pre-clearance. LIMS-integrated portals enable real-time dual-COA extraction, blockchain dual-isomer tracking, MRP replenishment. Volume frameworks unlock 22% tiered incentives.​

Infrastructure synchronizes federal forensic cycles and academic grant disbursements.

Legal & Regulatory Disclaimer

Distribution confines strictly to legitimate laboratory research, prohibiting human/veterinary administration, clinical investigation, diagnostic deployment, or consumptive applications. Recipients certify regulatory accountability spanning 21 USC §813 analogues, EU NPS 2004/757/JHA, national implementations. No liability for unauthorized diversions; mandatory dual-isomer End-Use Certification required. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.